Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lai Wei & Jia-Horng Kao. (2017) Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Current Medical Research and Opinion 33:3, pages 495-504.
Read now
Read now
Articles from other publishers (21)
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto & Man-Fung Yuen. (2023) The role of different viral biomarkers on the management of chronic hepatitis B. Clinical and Molecular Hepatology 29:2, pages 263-276.
Crossref
Crossref
Tung-Hung Su, Cheng-Yuan Peng, Shan-Han Chang, Tai-Chung Tseng, Chun-Jen Liu, Chi-Ling Chen, Chen-Hua Liu, Hung-Chih Yang, Pei-Jer Chen & Jia-Horng Kao. (2022) Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. Journal of the Formosan Medical Association 121:3, pages 703-711.
Crossref
Crossref
Xie Man & Rao Wei. (2022) Advancements in the prevention of hepatitis B recurrence by nucleos(t)ide analogue monotherapies after liver transplantation. European Journal of Inflammation 20, pages 1721727X2211392.
Crossref
Crossref
Lung-Yi Mak, Qi Huang, Danny Ka-Ho Wong, Luisa Stamm, Ka-Shing Cheung, Kwan-Lung Ko, Ran Yan, Lea Ouyang, James Fung, Wai-Kay Seto & Man-Fung Yuen. (2021) Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. Journal of Gastroenterology 56:5, pages 479-488.
Crossref
Crossref
Jonggi Choi & Young-Suk Lim. 2021. Hepatitis B Virus and Liver Disease. Hepatitis B Virus and Liver Disease
287
318
.
Chih-Lin Lin & Jia-Horng Kao. (2020) Hepatitis B. Gastroenterology Clinics of North America 49:2, pages 201-214.
Crossref
Crossref
Edward Gane, Daniel J. Verdon, Anna E. Brooks, Anuj Gaggar, Anh Hoa Nguyen, G. Mani Subramanian, Christian Schwabe & P. Rod Dunbar. (2019) Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. Journal of Hepatology 71:5, pages 900-907.
Crossref
Crossref
Lung‐Yi Mak, Michael Ko, Elvis To, Danny Ka‐Ho Wong, Justin Hei‐Chun Ma, Teresa Lok‐Yee Hui, Wai‐Kay Seto, James Fung, Ching‐Lung Lai & Man‐Fung Yuen. (2019) Serum Mac‐2‐binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir‐treated chronic hepatitis B patients. Journal of Gastroenterology and Hepatology 34:10, pages 1817-1823.
Crossref
Crossref
Rong-Nan Chien, Jia-Horng Kao, Cheng-Yuan Peng, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Tsung-Hui Hu, Hwa-I Yang, Sheng-Nan Lu, Yen-Hsuan Ni, Won-Long Chuang, Chuan-Mo Lee, Jaw-Chin Wu, Pei-Jer Chen & Yun-Fan Liaw. (2019) Taiwan consensus statement on the management of chronic hepatitis B. Journal of the Formosan Medical Association 118:1, pages 7-38.
Crossref
Crossref
Jia-Horng Kao. (2018) Hepatitis B: From control to cure. Journal of the Formosan Medical Association 117:10, pages 868-870.
Crossref
Crossref
Jonggi Choi & Young-Suk Lim. 2018. Hepatitis B Virus and Liver Disease. Hepatitis B Virus and Liver Disease
193
217
.
Tai-Chung Tseng & Jia-Horng Kao. (2017) Elimination of Hepatitis B: Is It a Mission Possible?. BMC Medicine 15:1.
Crossref
Crossref
Tung-Hung Su & Jia-Horng Kao. (2017) Unmet Needs in Clinical and Basic Hepatitis B Virus Research. The Journal of Infectious Diseases 216:suppl_8, pages S750-S756.
Crossref
Crossref
Tung-Hung Su & Chun-Jen Liu. (2017) Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut and Liver 11:5, pages 590-603.
Crossref
Crossref
Tung-Hung Su, Chung-Wai Shiau, Ping Jao, Nian-Jie Yang, Wei-Tien Tai, Chun-Jen Liu, Tai-Chung Tseng, Hung-Chih Yang, Chen-Hua Liu, Kai-Wen Huang, Ting-Chen Hu, Yu-Jen Huang, Yao-Ming Wu, Li-Ju Chen, Pei-Jer Chen, Ding-Shinn Chen, Kuen-Feng Chen & Jia-Horng Kao. (2017) Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Scientific Reports 7:1.
Crossref
Crossref
Tung-Hung Su & Jia-Horng Kao. (2017) Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International 37:2, pages 310-311.
Crossref
Crossref
Tongjing Xing, Hongtao Xu, Lin Cao & Maocong Ye. (2017) HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLOS ONE 12:1, pages e0169444.
Crossref
Crossref
Tung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, Yi-Hsiang Huang, Wan-Long Chuang, Chun-Che Lin, Chia-Chi Wang, Wei-Wen Su, Ming-Yao Chen, Cheng-Yuan Peng, Rong-Nan Chien, Yi-Wen Huang, Horng-Yuan Wang, Chih-Lin Lin, Sheng-Shun Yang, Tsung-Ming Chen, Lein-Ray Mo, Shih-Jer Hsu, Kuo-Chih Tseng, Tsai-Yuan Hsieh, Fat-Moon Suk, Chi-Tan Hu, Ming-Jong Bair, Cheng-Chao Liang, Yung-Chao Lei, Tai-Chung Tseng, Chi-Ling Chen & Jia-Horng Kao. (2016) Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International 36:12, pages 1755-1764.
Crossref
Crossref
Kerstin Schütte, Fathi Balbisi & Peter Malfertheiner. (2016) Prevention of Hepatocellular Carcinoma. Gastrointestinal Tumors 3:1, pages 37-43.
Crossref
Crossref
Jia-Horng Kao. (2015) Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 29:6, pages 907-917.
Crossref
Crossref
Hung-Chih Yang & Jia-Horng Kao. (2015) HBV cure—can we pin our hopes on immunotherapy?. Nature Reviews Gastroenterology & Hepatology 12:3, pages 129-131.
Crossref
Crossref